SCHEMBL6096596

SCHEMBL6096596

O=C(O)N1Cc2cccc(Cl)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM1 Q13255 4/20 0.40
PARP1 P09874 4/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40
NOTUM Q6P988 1/20 0.40
MAPT P10636 1/20 0.39
HSD17B3 P37058 1/20 0.39
AKR1B1 P15121 1/20 0.38
PREP P48147 1/20 0.36
BDKRB1 P46663 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
PARP2 Q9UGN5 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ESR1 P03372 1/20 0.35
POLB P06746 1/20 0.35
NR4A1 P22736 1/20 0.35
APEX1 P27695 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14996503 0.74 PARP1 (0.57) GRM1PARP1HTR2AHTR2CHTR2B
SCHEMBL30173026 0.74 HTR2A (0.42) GRM1PARP1HTR2AHTR2CHTR2B
SCHEMBL20325595 0.74 HTR2A (0.42) GRM1PARP1HTR2AHTR2CHTR2B
SCHEMBL803070 0.73 HTR2A (0.43) GRM1PARP1HTR2AHTR2CHTR2B
SCHEMBL31303406 0.73 GRM1 (0.40) GRM1NOTUMMAPTKDM4EPOLB
SCHEMBL15110419 0.72 SDCBP (0.48) GRM1PARP1MAPTKDM4EHSD17B10
SCHEMBL29606824 0.72 KDM4E (0.57) MAPTKDM4EHSD17B10TDP1ALDH1A1
SCHEMBL2065531 0.72 KDM4E (0.57) MAPTKDM4EHSD17B10TDP1ALDH1A1
SCHEMBL4716148 0.71 BDKRB1 (0.57) GRM1PARP1HTR2AHTR2CHTR2B
SCHEMBL4716160 0.71 RORC (0.42) GRM1PARP1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053122-B2 Therapeutic use of aryl amino acid derivatives PFIZER INC (US) 2006-05-30 US disclosed
EP-1528919-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES Pfizer Limited (GB) 2005-05-11 EP disclosed
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives MAW GRAHAM NIGEL (GB) 2004-07-15 US disclosed
WO-2004014357-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES PFIZER LIMITED (GB) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives CNR1, HCRTR1, HTR6 GRM1 4/4885PARP1 1810/4885HTR2A 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.